MFSD2B has been identified as the exclusive sphingosine-1-phosphate (S1P) transporter in
red blood cells (RBC) and platelets. MFSD2B-mediated S1P export from platelets is required …

Microfluidic technology has shown great application prospects in biochemical analysis, drug
delivery, disease diagnosis, and other fields. Magnetophoresis is an effective means to …

MYH9-related disease patients with mutations in the contractile protein nonmuscle myosin
heavy chain IIA display, among others, macrothrombocytopenia and a mild-to-moderate …

The fatality rate of non-small cell lung cancer (NSCLC) has been high due to the existence
of cancer stem cells (CSCs). Non-muscle myosin heavy chain 9 (MYH9) can promote the …

Pulmonary endothelial barrier dysfunction is a hallmark of clinical pulmonary edema and
contributes to the development of acute lung injury (ALI). Here we reported that ruscogenin …

The myosin heavy chain 9 (MYH9) gene encodes the heavy chain of non-muscle myosin IIA
(NMIIA), which belongs to the myosin II subfamily of actin-based molecular motors. Previous …

The biconcave disk shape of the mammalian red blood cell (RBC) is unique to the RBC and
is vital for its circulatory function. Due to the absence of a transcellular cytoskeleton, RBC …

In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9
mutations and kidney disease. The cardinal manifestation of MYH9-related disease is …

Lung cancer is, currently, one of the main malignancies causing deaths worldwide. To date,
early prognostic and diagnostic markers for small cell lung cancer (SCLC) have not been …

Mutations in the MYH9 gene result in macrothrombocytopenia often associated with
hemorrhages. Here, we studied the function and structure of platelets in three family …